Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Infective and inactivated filamentous phage as carriers for immunogenic peptides.

Samoylova TI, Norris MD, Samoylov AM, Cochran AM, Wolfe KG, Petrenko VA, Cox NR.

J Virol Methods. 2012 Jul;183(1):63-8. doi: 10.1016/j.jviromet.2012.03.032. Epub 2012 Apr 3.

PMID:
22575687
2.

Phage display allows identification of zona pellucida-binding peptides with species-specific properties: novel approach for development of contraceptive vaccines for wildlife.

Samoylova TI, Cochran AM, Samoylov AM, Schemera B, Breiteneicher AH, Ditchkoff SS, Petrenko VA, Cox NR.

J Biotechnol. 2012 Dec 31;162(2-3):311-8. doi: 10.1016/j.jbiotec.2012.10.006. Epub 2012 Oct 16.

PMID:
23079080
4.

Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: a comparative approach to conventional DNA vaccine.

Hashemi H, Bamdad T, Jamali A, Pouyanfard S, Mohammadi MG.

J Virol Methods. 2010 Feb;163(2):440-4. doi: 10.1016/j.jviromet.2009.11.008. Epub 2009 Nov 10.

PMID:
19903497
5.

Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.

Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL.

Virology. 2000 Mar 30;269(1):47-53.

6.

Generation and characterization of phage-GnRH chemical conjugates for potential use in cat and dog immunocontraception.

Samoylov A, Cox N, Cochran A, Wolfe K, Donovan C, Kutzler M, Petrenko V, Baker H, Samoylova T.

Reprod Domest Anim. 2012 Dec;47 Suppl 6:406-11. doi: 10.1111/rda.12061.

PMID:
23279551
7.
8.

Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.

van Houten NE, Zwick MB, Menendez A, Scott JK.

Vaccine. 2006 May 8;24(19):4188-200. Epub 2006 Jan 11.

10.

Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.

Cryz SJ Jr, Fürer E, Germanier R.

Dev Biol Stand. 1983;53:67-72.

PMID:
6873478
11.

Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.

Tsunetsugu-Yokota Y, Ato M, Takahashi Y, Hashimoto S, Kaji T, Kuraoka M, Yamamoto K, Mitsuki YY, Yamamoto T, Oshima M, Ohnishi K, Takemori T.

Jpn J Infect Dis. 2007 May;60(2-3):106-12.

12.

Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Henry KA, Murira A, van Houten NE, Scott JK.

Bioeng Bugs. 2011 Sep-Oct;2(5):275-83. doi: 10.4161/bbug.2.5.16559. Epub 2011 Sep 1.

13.

Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.

Ulivieri C, Citro A, Ivaldi F, Mascolo D, Ghittoni R, Fanigliulo D, Manca F, Baldari CT, Li Pira G, Del Pozzo G.

Immunol Lett. 2008 Aug 15;119(1-2):62-70. doi: 10.1016/j.imlet.2008.04.004. Epub 2008 May 19.

PMID:
18538862
14.
15.

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML.

J Clin Microbiol. 1989 Dec;27(12):2666-71.

18.
19.

Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb/c mice.

Yip YL, Smith G, Ward RL.

Immunol Lett. 2001 Dec 3;79(3):197-202.

PMID:
11600198
20.

Supplemental Content

Support Center